Program
PfSPZ Challenge
Also written as “PfSPZ Challenge (7G8)”, “PfSPZ Challenge (for CHMI)” and “PfSPZ Challenge (NF54)”.
Its studies are mostly in Malaria · Malaria, Falciparum, led by Sanaria.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanaria | 141 open or running | phase 1since Oct 22, 2009 | Oct 22, 2009 | Aug 30, 2027phase 1 · NCT06862453 |
Also a collaborator on its studies: marathon-oil-corporation and noble-oil-services.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 22, 2009First study: phase 1 study in Malaria, FalciparumFirst studyNCT01001650 · 80 enrolled · United States
- Mar 11, 2010Phase 1 study in MalariaNCT01086917 · 18 enrolled · Netherlands
- Feb 23, 2012Phase 1 study in MalariaNCT01540903 · 30 enrolled · Tanzania
- Jun 19, 2012Phase 1 study in MalariaNCT01624961 · 30 enrolled · Germany
- Nov 6, 2012Phase 1 study in MalariaNCT01728701 · 30 enrolled · Netherlands
- Jan 8, 2013Phase 1 study in MalariaNCT01771848 · 36 enrolled · Spain
- Apr 11, 20142 phase 1 studies in MalariaNCT02115516, NCT02132299
- Aug 27, 2014Phase 1 study in Malaria, FalciparumNCT02237586 · 25 enrolled · Gabon
- Nov 17, 2015Phase 1 study in MalariaNCT02613520 · 105 enrolled · Tanzania
- Mar 1, 2016Phase 1 study in MalariaNCT02704533 · 45 enrolled · Germany
- Jul 27, 2016Phase 1 study in MalariaNCT02859350 · 135 enrolled · Equatorial Guinea
- Dec 13, 2017Phase 1 study in MalariaNCT03420053 · 21 enrolled · Tanzania
- Mar 2, 2025Phase 1 study in Malaria, FalciparumNCT06862453 · 42 planned · Germany
Ahead
- Aug 30, 2027Primary completion: phase 1 study in Malaria, FalciparumNCT06862453
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06862453Malaria, Falciparum · Germany | 1 | Recruiting | Aug 30, 2027 | 42 |
| NCT03420053Malaria · Tanzania | 1 | Completed | Aug 25, 2018 | 21 |
| NCT02859350Malaria · Equatorial Guinea | 1 | Completed | Dec 2017 | 135 |
| NCT02704533Malaria · Germany | 1 | Completed | Oct 19, 2018 | 45 |
| NCT02613520Malaria · Tanzania | 1 | Completed | Feb 2017 | 105 |
| NCT02237586Malaria, Falciparum · Gabon | 1 | Completed | Sep 2014 | 25 |
| NCT02132299Malaria · Tanzania | 1 | Completed | Jul 2015 | 67 |
| NCT02115516Malaria · Germany | 1 | Completed | Dec 2015 | 67 |
| NCT01771848Malaria · Spain | 1 | Completed | May 2013 | 36 |
| NCT01728701Malaria · Netherlands | 1 | Completed | Dec 2013 | 30 |
| NCT01624961Malaria · Germany | 1 | Completed | Oct 2012 | 30 |
| NCT01540903Malaria · Tanzania | 1 | Completed | Sep 2012 | 30 |
| NCT01086917Malaria · Netherlands | 1 | Completed | Feb 2011 | 18 |
| NCT01001650Malaria, Falciparum · United States | 1 | Completed | Jul 2010 | 80 |
How it is read
Names in the registry
- “PfSPZ Challenge”, 9 entries
- “PfSPZ Challenge (7G8)”, 2 entries
- “PfSPZ Challenge (for CHMI)”, 2 entries
- “PfSPZ Challenge (NF54)”, 1 entry
- “PfSPZ Challenge (for PfSPZ-CVac)”, 1 entry
Codes read as this program: NF54.
Conditions, from the studies’ own filings
- Malaria, 8 studies
- Malaria, Falciparum, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.